 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE-- NBTXR3--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced positive new preclinical data investigating first-in-class radioenhancer NBTXR3, which is being evaluated as a tumor-agnostic, combo-agnostic product candidate across several tumor types. The data is being shared via poster 